22.75

0.00% 0.00

After Hours: 22.50 -0.25 -1.10%

Cidara Therapeutics Inc (CDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Cidara Therapeutics Inc stock is traded at $22.75, with a volume of 186.61K. It is up +0.00% in the last 24 hours and down -4.45% over the past month. Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Previous Close:

$22.75

Open:

$22.84

24h Volume:

186.61K

Relative Volume:

1.82

Market Cap:

$249.19M

Revenue:

$56.54M

Net Income/Loss:

$-30.70M

P/E Ratio:

-58.33

EPS:

-0.39

Net Cash Flow:

$-31.05M

1W Performance:

-1.09%

1M Performance:

-4.45%

6M Performance:

+94.11%

1Y Performance:

+59.27%

1-Day Range:

$22.04

$23.21

1-Week Range:

$21.30

$23.44

52-Week Range:

$10.00

$28.42

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name

Cidara Therapeutics Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

858-752-6170

Address

6310 NANCY RIDGE DRIVE, SAN DIEGO, CA

Employee

Twitter

@CidaraThera

Next Earnings Date

2024-10-31

Latest SEC Filings

CDTX's Discussions on Twitter

Compare CDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CDTX Cidara Therapeutics Inc	22.75	249.19M	56.54M	-30.70M	-31.05M	-0.39
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-25	Initiated	Citizens JMP	Mkt Outperform
Jan-27-25	Resumed	Cantor Fitzgerald	Overweight
Dec-13-24	Initiated	RBC Capital Mkts	Outperform
Nov-08-24	Initiated	Guggenheim	Buy
Aug-14-24	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-03-21	Resumed	H.C. Wainwright	Buy
Sep-22-21	Upgrade	WBB Securities	Buy → Strong Buy
Mar-04-21	Initiated	Aegis Capital	Buy
Sep-04-19	Upgrade	Wedbush	Neutral → Outperform
Jul-26-18	Initiated	Citigroup	Buy
Apr-21-17	Initiated	Raymond James	Strong Buy
Apr-17-17	Reiterated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Ladenburg Thalmann	Buy
Apr-11-17	Resumed	Wedbush	Outperform
Feb-22-17	Reiterated	H.C. Wainwright	Buy
Feb-22-17	Upgrade	WBB Securities	Sell → Hold
Dec-21-16	Resumed	Leerink Partners	Outperform
Dec-19-16	Initiated	H.C. Wainwright	Buy
Sep-23-16	Downgrade	WBB Securities	Hold → Sell
Oct-09-15	Upgrade	WBB Securities	Sell → Hold
May-11-15	Initiated	Jefferies	Buy
May-11-15	Initiated	Leerink Partners	Outperform
May-11-15	Initiated	Needham	Buy
May-11-15	Initiated	Wedbush	Outperform
Apr-23-15	Initiated	WBB Securities	Sell

View All

Cidara Therapeutics Inc Stock (CDTX) Latest News

08:12 AM

Cidara Therapeutics to Participate in World Health - GlobeNewswire

08:12 AM

Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance

08:12 AM

08:00 AM

Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan

08:00 AM

06:22 AM

Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World

06:22 AM

Mar 18, 2025

Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire

Mar 18, 2025

Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan

Mar 18, 2025

Mar 17, 2025

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire

Mar 17, 2025

Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan

Mar 17, 2025

Mar 16, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World

Mar 16, 2025

Mar 14, 2025

(CDTX) Long Term Investment Analysis - Stock Traders Daily

Mar 14, 2025

Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 14, 2025

Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia

Mar 13, 2025

Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India

Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India

Mar 13, 2025

Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 13, 2025

Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com UK

Mar 13, 2025

HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World

Mar 13, 2025

Mar 12, 2025

Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq

Mar 12, 2025

Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha

Mar 12, 2025

Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks

Mar 12, 2025

Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada

Mar 12, 2025

FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World

Mar 12, 2025

Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks

Mar 12, 2025

Mar 11, 2025

HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World

Mar 11, 2025

Mar 10, 2025

Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada

Mar 10, 2025

Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks

Mar 10, 2025

Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks

Mar 10, 2025

Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World

Mar 10, 2025

Mar 09, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 09, 2025

Mar 08, 2025

Cidara Therapeutics Faces Financial Risks Amid Delayed Annual Report Filing - TipRanks

Mar 08, 2025

Mar 07, 2025

Cidara Therapeutics Advances with Strong Financial Backing - TipRanks

Mar 07, 2025

Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Scinai Immunotherapeutics (NASDAQ:SCNI) - Defense World

Mar 07, 2025

Mar 06, 2025

Cidara Therapeutics: Q4 Earnings Snapshot - Barchart

Mar 06, 2025

Cidara Therapeutics reports wider Q4 loss, shares dip - Investing.com

Mar 06, 2025

Cidara Therapeutics reports wider Q4 loss, shares dip By Investing.com - Investing.com South Africa

Mar 06, 2025

Cidara Therapeutics: Q4 Earnings Snapshot -March 06, 2025 at 05:03 pm EST - Marketscreener.com

Mar 06, 2025

Cidara Therapeutics Completes Enrollment in Phase 2b NAVIGATE Trial and Secures $105 Million in Financing - Nasdaq

Mar 06, 2025

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 06, 2025

Can Cidara's $196M War Chest and 5,000-Patient Trial Transform Flu Prevention? - StockTitan

Mar 06, 2025

Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 06, 2025

Mar 04, 2025

(CDTX) Trading Signals - Stock Traders Daily

Mar 04, 2025

Feb 26, 2025